CAS 37762-06-4|Zaprinast
| Common Name | Zaprinast | ||
|---|---|---|---|
| CAS Number | 37762-06-4 | Molecular Weight | 271.275 |
| Density | 1.484g/cm3 | Boiling Point | 406.3±47.0 °C at 760 mmHg |
| Molecular Formula | C13H13N5O2 | Melting Point | 237-238ºC dec. |
| MSDS | ChineseUSA | Flash Point | 199.5±29.3 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | zaprinast |
|---|---|
| Synonym | More Synonyms |
Zaprinast BiologicalActivity
| Description | Zaprinast (M&B 22948) is an inhibitor of cGMP-selective Phosphodiesterases(PDEs)[1]. Zaprinast is a G protein-coupled receptor (GPR) 35 agonist which activates rat GPR35 strongly and activates human GPR35 moderately[2]. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects[3]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>Phosphodiesterase (PDE)Signaling Pathways >>GPCR/G Protein >>CXCRSignaling Pathways >>Immunology/Inflammation >>CXCRResearch Areas >>Neurological Disease |
| Target | PDE[1], GPR35[2] |
| References | [1]. Choi SH , et al. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res. 2002 Feb 1;67(3):411-21. [2]. Taniguchi Y, et al. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 2006 Sep 18;580(21):5003-8. Epub 2006 Aug 17. [3]. Keswani AN , et al The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects. J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):116-24. |
Chemical & Physical Properties
| Density | 1.484g/cm3 |
|---|---|
| Boiling Point | 406.3±47.0 °C at 760 mmHg |
| Melting Point | 237-238ºC dec. |
| Molecular Formula | C13H13N5O2 |
| Molecular Weight | 271.275 |
| Flash Point | 199.5±29.3 °C |
| Exact Mass | 271.106934 |
| PSA | 96.55000 |
| LogP | 0.17 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.719 |
| Storage condition | 2-8℃ |
| Water Solubility | Soluble to 100 mM in DMSO |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26;S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | XZ6157358 |
Articles34
More Articles| Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells. PLoS ONE 9(12) , e114019, (2014) Nicotinamide phosphoribosyltransferase (NAMPT) plays an important role in cellular bioenergetics. It is responsible for converting nicotinamide to nicotinamide adenine dinucleotide, an essential molec... | |
| Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J. Biol. Chem. 288(50) , 36129-40, (2013) Transport of pyruvate into mitochondria by the mitochondrial pyruvate carrier is crucial for complete oxidation of glucose and for biosynthesis of amino acids and lipids. Zaprinast is a well known pho... | |
| GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS ONE 8 , e82180, (2013) Limited information is available on the brain expression and role of GPR35, a Gi/o coupled receptor activated by kynurenic acid (KYNA). In mouse cultured astrocytes, we detected GPR35 transcript using... |
Synonyms
| 1H-1,2,3-triazolo[4,5-d]pyrimidin-7-ol, 5-(2-propoxyphenyl)- |
| 2-(2-PROPYLOXYPHENYL)-8-AZAPURIN-6-ONE |
| 5-(2-Propoxyphenyl)-1,4-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| 2-o-propoxyphenyl-8-azapurin-6-one |
| EINECS 253-655-1 |
| Potassium phosphate monobasic |
| Zaprinast |
| 3,6-dihydro-5-(2-propoxyphenyl) |
| Phenylaza purinon |
| 2-(2-Propoxyphenyl)-8-azahypoxanthine |
| MFCD00214073 |
| 5-(2-Propoxyphenyl)-2,3-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| 7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one, 3,4-dihydro-5-(2-propoxyphenyl)- |
| B 22,948 |
| 8-Aza-2-(2-propoxyphenyl)-6-purinone |
| 5-(2-propoxyphenyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol |
| 1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one |
| 7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one, 1,4-dihydro-5-(2-propoxyphenyl)- |
| 5-(2-Propoxyphenyl)-3,4-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| 1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one |
| 1,4-Dihydro-5-(2-propoxyphenyl)-1,2,3-triazolo[4,5-d]pyrimidin-7-one |
| 7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one, 2,3-dihydro-5-(2-propoxyphenyl)- |
